Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to -$4.1 million.

  • Heron Therapeutics' Net Income towards Common Stockholders rose 818.75% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 10616.1%. This contributed to the annual value of -$14.0 million for FY2024, which is 8739.19% up from last year.
  • Per Heron Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$4.1 million for Q3 2025, which was up 818.75% from -$1.6 million recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Net Income towards Common Stockholders peaked at $4.2 million during Q4 2024, and registered a low of -$62.9 million during Q1 2022.
  • For the 5-year period, Heron Therapeutics' Net Income towards Common Stockholders averaged around -$27.2 million, with its median value being -$24.9 million (2023).
  • Per our database at Business Quant, Heron Therapeutics' Net Income towards Common Stockholders tumbled by 2074.11% in 2022 and then surged by 16573.57% in 2025.
  • Over the past 5 years, Heron Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$53.5 million in 2021, then surged by 61.98% to -$20.4 million in 2022, then surged by 49.79% to -$10.2 million in 2023, then skyrocketed by 140.83% to $4.2 million in 2024, then plummeted by 198.08% to -$4.1 million in 2025.
  • Its Net Income towards Common Stockholders was -$4.1 million in Q3 2025, compared to -$1.6 million in Q2 2025 and $3.2 million in Q1 2025.